FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094105410> ?p ?o ?g. }

• W3094105410 endingPage "732" @default.
• W3094105410 startingPage "725" @default.
• W3094105410 abstract "Objective We sought to evaluate COVID-19 clinical course in patients with IBD treated with different medication classes and combinations. Design Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is a large, international registry created to monitor outcomes of IBD patients with confirmed COVID-19. We used multivariable regression with a generalised estimating equation accounting for country as a random effect to analyse the association of different medication classes with severe COVID-19, defined as intensive care unit admission, ventilator use and/or death. Results 1439 cases from 47 countries were included (mean age 44.1 years, 51.4% men) of whom 112 patients (7.8%) had severe COVID-19. Compared with tumour necrosis factor (TNF) antagonist monotherapy, thiopurine monotherapy (adjusted OR (aOR) 4.08, 95% CI 1.73 to 9.61) and combination therapy with TNF antagonist and thiopurine (aOR 4.01, 95% CI 1.65 to 9.78) were associated with an increased risk of severe COVID-19. Any mesalamine/sulfasalazine compared with no mesalamine/sulfasalazine use was associated with an increased risk (aOR 1.70, 95% CI 1.26 to 2.29). This risk estimate increased when using TNF antagonist monotherapy as a reference group (aOR 3.52, 95% CI 1.93 to 6.45). Interleukin-12/23 and integrin antagonists were not associated with significantly different risk than TNF antagonist monotherapy (aOR 0.98, 95% CI 0.12 to 8.06 and aOR 2.42, 95% CI 0.59 to 9.96, respectively). Conclusion Combination therapy and thiopurines may be associated with an increased risk of severe COVID-19. No significant differences were observed when comparing classes of biologicals. These findings warrant confirmation in large population-based cohorts. MKH should be changed to MDK for co-last author line" @default.
• W3094105410 created "2020-10-29" @default.
• W3094105410 creator A5007400614 @default.
• W3094105410 creator A5013058329 @default.
• W3094105410 creator A5015470174 @default.
• W3094105410 creator A5027876343 @default.
• W3094105410 creator A5033087694 @default.
• W3094105410 creator A5035990606 @default.
• W3094105410 creator A5037368935 @default.
• W3094105410 creator A5041936168 @default.
• W3094105410 creator A5043503140 @default.
• W3094105410 creator A5055227173 @default.
• W3094105410 creator A5062572039 @default.
• W3094105410 creator A5072432144 @default.
• W3094105410 creator A5074999356 @default.
• W3094105410 creator A5087115404 @default.
• W3094105410 date "2020-10-20" @default.
• W3094105410 modified "2023-10-18" @default.
• W3094105410 title "Effect of IBD medications on COVID-19 outcomes: results from an international registry" @default.
• W3094105410 cites W1547943993 @default.
• W3094105410 cites W1568390176 @default.
• W3094105410 cites W1964098393 @default.
• W3094105410 cites W1998196835 @default.
• W3094105410 cites W2010767372 @default.
• W3094105410 cites W2766046358 @default.
• W3094105410 cites W2794595980 @default.
• W3094105410 cites W2797152839 @default.
• W3094105410 cites W2808733186 @default.
• W3094105410 cites W2883862625 @default.
• W3094105410 cites W2901862653 @default.
• W3094105410 cites W2919081348 @default.
• W3094105410 cites W3005403371 @default.
• W3094105410 cites W3008028633 @default.
• W3094105410 cites W3008554056 @default.
• W3094105410 cites W3008827533 @default.
• W3094105410 cites W3011605790 @default.
• W3094105410 cites W3011610993 @default.
• W3094105410 cites W3012738153 @default.
• W3094105410 cites W3012925204 @default.
• W3094105410 cites W3013789297 @default.
• W3094105410 cites W3014493418 @default.
• W3094105410 cites W3015861468 @default.
• W3094105410 cites W3023787531 @default.
• W3094105410 cites W3024177957 @default.
• W3094105410 cites W3025190337 @default.
• W3094105410 cites W3035816392 @default.
• W3094105410 cites W3080981445 @default.
• W3094105410 cites W4211138554 @default.
• W3094105410 cites W4229808289 @default.
• W3094105410 cites W4247938048 @default.
• W3094105410 cites W4293777482 @default.
• W3094105410 doi "https://doi.org/10.1136/gutjnl-2020-322539" @default.
• W3094105410 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8136807" @default.
• W3094105410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33082265" @default.
• W3094105410 hasPublicationYear "2020" @default.
• W3094105410 type Work @default.
• W3094105410 sameAs 3094105410 @default.
• W3094105410 citedByCount "227" @default.
• W3094105410 countsByYear W30941054102020 @default.
• W3094105410 countsByYear W30941054102021 @default.
• W3094105410 countsByYear W30941054102022 @default.
• W3094105410 countsByYear W30941054102023 @default.
• W3094105410 crossrefType "journal-article" @default.
• W3094105410 hasAuthorship W3094105410A5007400614 @default.
• W3094105410 hasAuthorship W3094105410A5013058329 @default.
• W3094105410 hasAuthorship W3094105410A5015470174 @default.
• W3094105410 hasAuthorship W3094105410A5027876343 @default.
• W3094105410 hasAuthorship W3094105410A5033087694 @default.
• W3094105410 hasAuthorship W3094105410A5035990606 @default.
• W3094105410 hasAuthorship W3094105410A5037368935 @default.
• W3094105410 hasAuthorship W3094105410A5041936168 @default.
• W3094105410 hasAuthorship W3094105410A5043503140 @default.
• W3094105410 hasAuthorship W3094105410A5055227173 @default.
• W3094105410 hasAuthorship W3094105410A5062572039 @default.
• W3094105410 hasAuthorship W3094105410A5072432144 @default.
• W3094105410 hasAuthorship W3094105410A5074999356 @default.
• W3094105410 hasAuthorship W3094105410A5087115404 @default.
• W3094105410 hasBestOaLocation W30941054101 @default.
• W3094105410 hasConcept C107130276 @default.
• W3094105410 hasConcept C126322002 @default.
• W3094105410 hasConcept C2778260677 @default.
• W3094105410 hasConcept C2779134260 @default.
• W3094105410 hasConcept C2779383735 @default.
• W3094105410 hasConcept C2780479503 @default.
• W3094105410 hasConcept C70917649 @default.
• W3094105410 hasConcept C71924100 @default.
• W3094105410 hasConcept C90924648 @default.
• W3094105410 hasConceptScore W3094105410C107130276 @default.
• W3094105410 hasConceptScore W3094105410C126322002 @default.
• W3094105410 hasConceptScore W3094105410C2778260677 @default.
• W3094105410 hasConceptScore W3094105410C2779134260 @default.
• W3094105410 hasConceptScore W3094105410C2779383735 @default.
• W3094105410 hasConceptScore W3094105410C2780479503 @default.
• W3094105410 hasConceptScore W3094105410C70917649 @default.
• W3094105410 hasConceptScore W3094105410C71924100 @default.
• W3094105410 hasConceptScore W3094105410C90924648 @default.
• W3094105410 hasFunder F4320309446 @default.
• W3094105410 hasFunder F4320332161 @default.

• next